Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PCVX 
Vaxcyte Inc (PCVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: PCVX (3-star) is a STRONG-BUY. BUY since 46 days. Simulated Profits (32.43%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $92
1 Year Target Price $92
| 9 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 70.57% | Avg. Invested days 47 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.03B USD | Price to earnings Ratio - | 1Y Target Price 92 |
Price to earnings Ratio - | 1Y Target Price 92 | ||
Volume (30-day avg) 10 | Beta 1.29 | 52 Weeks Range 27.66 - 94.60 | Updated Date 12/5/2025 |
52 Weeks Range 27.66 - 94.60 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.07% | Return on Equity (TTM) -20.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4617351745 | Price to Sales(TTM) - |
Enterprise Value 4617351745 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -14.43 | Shares Outstanding 130906263 | Shares Floating 117926907 |
Shares Outstanding 130906263 | Shares Floating 117926907 | ||
Percent Insiders 0.64 | Percent Institutions 110.46 |
Upturn AI SWOT
Vaxcyte Inc
Company Overview
History and Background
Vaxcyte, Inc. (PCVX) is a vaccine innovation company founded in 2013. They are focused on developing and commercializing novel vaccines to prevent or treat infectious diseases. They went public in 2020.
Core Business Areas
- Vaccine Development: Focused on developing novel and improved versions of existing vaccines, as well as new vaccines for unmet needs. Primarily focused on pneumococcal conjugate vaccines (PCV).
Leadership and Structure
Grant Pickering is the CEO. The company has a typical organizational structure for a biotechnology company, with departments for research and development, clinical trials, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Vaxcyte's lead product candidate, VAX-24: A 24-valent pneumococcal conjugate vaccine (PCV) designed to improve upon existing PCVs like Prevnar 20. Currently in clinical development, it does not yet have market share. Competitors are Pfizer (Prevnar 20) and Merck.
- VAX-31: A 31-valent PCV vaccine. Currently in early development stages. Competitors are Pfizer (Prevnar 20) and Merck.
Market Dynamics
Industry Overview
The vaccine market is large and growing, driven by increasing awareness of the importance of vaccination, aging populations, and the emergence of new infectious diseases. The pneumococcal vaccine market is dominated by Pfizer.
Positioning
Vaxcyte aims to compete with existing pneumococcal vaccines by offering broader serotype coverage and improved immune response. They are in the clinical stage, attempting to demonstrate superior efficacy compared to existing products.
Total Addressable Market (TAM)
The global pneumococcal vaccine market is estimated to be $7-8 billion annually. Vaxcyte is positioned to capture a portion of this TAM if their vaccines are approved and demonstrate superior performance.
Upturn SWOT Analysis
Strengths
- Novel vaccine technology platform
- Experienced management team
- Strong intellectual property portfolio
- Focus on large and growing market
Weaknesses
- Clinical stage company with no approved products
- Dependent on clinical trial success
- High cash burn rate
- Competition from established players
Opportunities
- Positive clinical trial results
- Partnerships with pharmaceutical companies
- Expansion into new vaccine areas
- Acquisition by a larger company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing vaccines
- Patent challenges
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- PFE
- MRK
Competitive Landscape
Vaxcyte faces competition from established players with approved products. Their advantage lies in the potential for superior efficacy and broader coverage.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in terms of R&D spending and clinical trial progress. No revenue yet, so no 'growth' is considered from that area.
Future Projections: Future growth depends on clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Initiation and progression of clinical trials for VAX-24 and VAX-31.
Summary
Vaxcyte is a clinical-stage vaccine company with promising technology but significant risks. Their success hinges on positive clinical trial results and regulatory approval. The competitive landscape is challenging, but the potential market is large. Current investors are betting on the future potential of the vaccine pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Vaxcyte Inc. Investor Relations, SEC Filings, Analyst Reports, Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vaxcyte Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2020-06-12 | Co-Founder, CEO & Director Mr. Grant E. Pickering M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 414 | Website https://vaxcyte.com |
Full time employees 414 | Website https://vaxcyte.com | ||
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.